ClinicalTrials.Veeva

Menu

The Predictive Value of Hepatocyte Growth Factor and Soluble Receptor s-Met in Sepsis

J

Jingyuan,Xu

Status

Unknown

Conditions

Sepsis

Treatments

Other: taking peripheral blood

Study type

Observational

Funder types

Other

Identifiers

NCT03340649
2017ZDSYLL095-P01

Details and patient eligibility

About

To observe the changes of plasma hepatocyte growth factor and soluble receptor s-Met levels in patients with sepsis, and to explore its clinical significance.

Full description

90 patients who diagnosed as sepsis were included in this study. Then keep blood samples from these patients in the first day, the third day, detect the hepatocyte growth factor and soluble receptor s-Met level in plasma byenzyme-linked immuno sorbent assay. Record Severity of illness and survival status of every patient within 28 days. Objective to evaluate the correlation between the level of hepatocyte growth factor and soluble receptor s-Met in plasma and the prognosis of the patients.

Enrollment

90 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Patients admitted to ICU diagnosed of sepsis(sepsis3.0 criteria)
  2. Patients signing informed consent

Exclusion criteria

  1. Age is less than 18 years old or more than 80 years old
  2. Pregnant women
  3. Patients with tumor、hepatitis、liver cirrhosis、acute myocardial infarction、chronic renal tubular nephritis、interstitial pneumonia、acute pancreatitis、systemic lupus erythenatosus、ulcerative colitis、crohn's disease、HELLP syndrome
  4. Prothrombin time is extension in patients with after liver transplantation
  5. Patients with chronic renal failure
  6. Patients after kidney transplantation

Trial contacts and locations

1

Loading...

Central trial contact

chenglong liang, master; yi yang, doctor

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems